Indications Fincor tablet is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, nonfatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).

Pharmacology Finerenone is a nonsteroidal, selective antagonist of the mineralocorticoid receptor (MR). It blocks MR-mediated sodium reabsorption and MR overactivation in kidney, heart, and blood vessels, thereby reducing fibrosis and inflammation. Finerenone shows high potency and selectivity for MR without relevant affinity for androgen, progesterone, estrogen, or glucocorticoid receptors. It slightly reduces blood pressure and does not prolong QT interval at therapeutic doses. It is metabolized mainly by CYP3A4 and excreted mostly in urine.

Dosage & Administration

eGFR ≥ 60 mL/min/1.73 m²: 20 mg once daily
eGFR 25–<60 mL/min/1.73 m²: 10 mg once daily
eGFR <25 mL/min/1.73 m²: not recommended Target dose: 20 mg once daily. Monitor serum potassium after 4 weeks and adjust dose accordingly.

Interactions

Strong CYP3A4 inhibitors: contraindicated (e.g., grapefruit juice).
Moderate/weak CYP3A4 inhibitors: monitor potassium and adjust dose.
Strong/moderate CYP3A4 inducers: avoid use (reduce efficacy).

Contraindications Contraindicated with strong CYP3A4 inhibitors and in patients with adrenal insufficiency.

Side Effects Adverse reactions occurring in ≥1% of patients include hyperkalemia, hypotension, and hyponatremia.